Limits...
Association between β2-Adrenergic Receptor-16Arg/Gly Gene Polymorphism and Chronic Obstructive Pulmonary Disease Risk:Systematic Review and Meta-Analysis.

Wang W, Li P, Chen Y, Yang J - Iran. J. Public Health (2014)

Bottom Line: However, the results were inconclusive.Gly) (dominant model: OR = 1.45, 95% CI = 1.04-2.01, P = 0.311 for heterogeneity, z = 2.22, P = 0.026 for OR; allele model: OR = 1.27, 95% CI = 1.03-1.57, P = 0.209 for heterogeneity, z = 2.20, P = 0.028 for OR), but not in other subgroups.More studies with larger sample sizes are needed to validate the results.

View Article: PubMed Central - PubMed

Affiliation: Dept. of Respiratory Medicine, Zhongnan Hospital of Wuhan University , Wuhan, Hubei 430071, China.

ABSTRACT

Background: The association between β2-adrenergic receptor (ADRB2) -16Arg/Gly polymorphism (rs1042713) and chronic obstructive pulmonary disease (COPD) risk has been investigated in many published studies. However, the results were inconclusive. A meta-analysis was performed to make a more precise estimation of the relationship.

Methods: The PubMed, EMBASE, ISI web of science, the Cochrane Database of Systematic Reviews, and Chinese databases (CNKI, Wanfang Data, CBM, VIP) were searched for published literature. Odds ratios (OR) with 95% confidence interval (CI) were used to assess the strength of association.

Results: Eleven studies, comprising 1,128 COPD patients and 1,182 controls, were included in the meta-analysis. Overall, there was no significant association between the ADRB2-16Arg/Gly polymorphism and COPD risk in general population. In the stratification analysis by potential confounding variables, significant associations were observed between the ADRB2-16Arg/Gly polymorphism and COPD risk among smoking Asians under the dominant genetic model and allele model (Arg vs. Gly) (dominant model: OR = 1.45, 95% CI = 1.04-2.01, P = 0.311 for heterogeneity, z = 2.22, P = 0.026 for OR; allele model: OR = 1.27, 95% CI = 1.03-1.57, P = 0.209 for heterogeneity, z = 2.20, P = 0.028 for OR), but not in other subgroups.

Conclusion: This meta-analysis suggested that the ADRB2-16Arg/Gly polymorphism might be a potential risk factor for the development of COPD in smoking Asian populations, but not in European descendents, and tobacco smoking probably increased the genetic susceptibility. More studies with larger sample sizes are needed to validate the results.

No MeSH data available.


Related in: MedlinePlus

Flow diagram of the meta-analysis
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4401053&req=5

Figure 1: Flow diagram of the meta-analysis

Mentions: Twelve published articles evaluating an association between ADRB2-16Arg/Gly polymorphism and COPD risk were collected (12-19, 29-32). Of these, one was excluded from our meta-analysis due to lack of its agreement to HWE (29). In addition, two articles were published by the same author using the same data available (17, 30), thus we selected the most recent and complete one (17). Therefore, 10 publications met the inclusion criteria (12-19, 31, 32). Among these publications, one publication (12) included two studies (Hegab AE-1 and Hegab AE-2) according to different ethnicity, so each study in this article was considered separately for pooling analyses. Finally, there were 11 eligible studies in this final analysis. Six studies were involved in Asian subjects and five in European descendent subjects. Detailed characteristics of the studies included in this meta-analysis are given in Table 1 and 2. The literature search procedures are shown in Fig. 1.


Association between β2-Adrenergic Receptor-16Arg/Gly Gene Polymorphism and Chronic Obstructive Pulmonary Disease Risk:Systematic Review and Meta-Analysis.

Wang W, Li P, Chen Y, Yang J - Iran. J. Public Health (2014)

Flow diagram of the meta-analysis
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4401053&req=5

Figure 1: Flow diagram of the meta-analysis
Mentions: Twelve published articles evaluating an association between ADRB2-16Arg/Gly polymorphism and COPD risk were collected (12-19, 29-32). Of these, one was excluded from our meta-analysis due to lack of its agreement to HWE (29). In addition, two articles were published by the same author using the same data available (17, 30), thus we selected the most recent and complete one (17). Therefore, 10 publications met the inclusion criteria (12-19, 31, 32). Among these publications, one publication (12) included two studies (Hegab AE-1 and Hegab AE-2) according to different ethnicity, so each study in this article was considered separately for pooling analyses. Finally, there were 11 eligible studies in this final analysis. Six studies were involved in Asian subjects and five in European descendent subjects. Detailed characteristics of the studies included in this meta-analysis are given in Table 1 and 2. The literature search procedures are shown in Fig. 1.

Bottom Line: However, the results were inconclusive.Gly) (dominant model: OR = 1.45, 95% CI = 1.04-2.01, P = 0.311 for heterogeneity, z = 2.22, P = 0.026 for OR; allele model: OR = 1.27, 95% CI = 1.03-1.57, P = 0.209 for heterogeneity, z = 2.20, P = 0.028 for OR), but not in other subgroups.More studies with larger sample sizes are needed to validate the results.

View Article: PubMed Central - PubMed

Affiliation: Dept. of Respiratory Medicine, Zhongnan Hospital of Wuhan University , Wuhan, Hubei 430071, China.

ABSTRACT

Background: The association between β2-adrenergic receptor (ADRB2) -16Arg/Gly polymorphism (rs1042713) and chronic obstructive pulmonary disease (COPD) risk has been investigated in many published studies. However, the results were inconclusive. A meta-analysis was performed to make a more precise estimation of the relationship.

Methods: The PubMed, EMBASE, ISI web of science, the Cochrane Database of Systematic Reviews, and Chinese databases (CNKI, Wanfang Data, CBM, VIP) were searched for published literature. Odds ratios (OR) with 95% confidence interval (CI) were used to assess the strength of association.

Results: Eleven studies, comprising 1,128 COPD patients and 1,182 controls, were included in the meta-analysis. Overall, there was no significant association between the ADRB2-16Arg/Gly polymorphism and COPD risk in general population. In the stratification analysis by potential confounding variables, significant associations were observed between the ADRB2-16Arg/Gly polymorphism and COPD risk among smoking Asians under the dominant genetic model and allele model (Arg vs. Gly) (dominant model: OR = 1.45, 95% CI = 1.04-2.01, P = 0.311 for heterogeneity, z = 2.22, P = 0.026 for OR; allele model: OR = 1.27, 95% CI = 1.03-1.57, P = 0.209 for heterogeneity, z = 2.20, P = 0.028 for OR), but not in other subgroups.

Conclusion: This meta-analysis suggested that the ADRB2-16Arg/Gly polymorphism might be a potential risk factor for the development of COPD in smoking Asian populations, but not in European descendents, and tobacco smoking probably increased the genetic susceptibility. More studies with larger sample sizes are needed to validate the results.

No MeSH data available.


Related in: MedlinePlus